Q4 2024 LifeMD Inc Earnings Call Transcript
Key Points
- LifeMD Inc (LFMD) reported a 43% increase in consolidated revenue for the fourth quarter, reaching $64.3 million.
- Telehealth revenue grew by 60% year-over-year, with adjusted EBITDA increasing nearly five-fold.
- The company successfully launched several key products, including a male hormone replacement therapy business and a nationwide pharmacy licensed in 47 states.
- LifeMD Inc (LFMD) plans to expand its virtual primary care offerings, including a new LifeMD Plus membership program and behavioral health services.
- The company is optimistic about the potential growth of its Medicare offerings, which are set to launch soon, targeting a significant market of Medicare beneficiaries.
- Gross margin for the fourth quarter declined by 280 basis points to 85.3% due to changes in revenue mix and one-time impacts related to onboarding a new pharmacy.
- LifeMD Inc (LFMD) reported a GAAP net loss attributable to common stockholders of $883,000 for the fourth quarter.
- The company faces challenges in the highly fragmented GLP-1 supported weight loss market, with many smaller competitors.
- There are uncertainties regarding the FDA's stance on compounded GLP-1 medications, which could impact LifeMD's offerings.
- The company is still in the early stages of expanding its insurance offerings, with a relatively small contribution to revenue expected from insured lives in 2025.
Good afternoon. Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer.
Following management's prepared remarks, we will open the call for a question-and-answer session.
Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time.
Forward-looking statements made during this call are based on current information available to the company as of today, March 10, 2025. The company assumes no obligation to update or revise any forward-looking statements after today's call except as required by law.
Also, please note that management will be discussing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
